DNLI News and Press, Denali Therapeutics Inc. From 06/17/25

2025-06-17 21:14:09 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers' 13F stock portfolio on a quarterly basis. It is based on Baker Brothers' regulatory 13F Form filed on 05/15/2025. The 13F portfolio value decreased from $...

2025-06-13 20:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-05-06 17:05:00 ET More on Denali Therapeutics Denali Therapeutics: Vast Pipeline, First Approval Up Ahead Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing Seeking Alpha’s Quant Rating on Denali Therapeutics Historical e...

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. “The completion of our BLA submission for tividenofusp alfa represents a ...

Cyclerion Therapeutics Inc. (CYCN) is expected to report for Q1 2025 Standard BioTools Inc. (LAB) is expected to report $-0.06 for Q1 2025 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2025 CF Bankshares Inc. (CFBK) is expected to report for Q1 2025 Jack Henry & A...

2025-05-05 18:48:26 ET Denali Therapeutics Inc. (DNLI) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.84%. The average open to low on the day of earnings was -3.32%. The average open ...

2025-05-05 18:43:25 ET Denali Therapeutics Inc. (DNLI) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in DNLI stock price following earnings has averaged ±2.50% , with a median of 1.14%....

Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026 Alignment through recent interactions with CDER on path to accelerated approval and conversion to full approval for tividenofusp alfa Productive ...

2025-03-28 09:00:39 ET Summary RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with stability and specificity. Alnylam, Ionis, and Sarepta lead the RNA therapeutics market, with Alnylam showing the most promis...

2025-03-20 14:16:45 ET Summary Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, wit...